echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Representatives of Japan Pharmaceutical Industry Association visited China Pharmaceutical Promotion Association

    Representatives of Japan Pharmaceutical Industry Association visited China Pharmaceutical Promotion Association

    • Last Update: 2017-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: China pharmaceutical innovation promotion association may 25, 2017, China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") )Zhang Dan, chairman of the pharmaceutical research and Development Committee, chairman of Fang en (Tianjin) Pharmaceutical Development Co., Ltd., Wang Yinxiang, vice chairman and President and chief scientist of Beida Pharmaceutical Co., Ltd., met with Atsushi, leader of the pharmaceutical development alliance working group of Japan Pharmaceutical Industry Association (JPMA) and senior director of Takeda pharmaceutical Dr hasuoka and his delegation were accompanied by Shingo Yamasaki, researcher of drug discovery department and member of daewg, noriyuki Matsumoto, director of JPMA biopharmaceutical regulatory affairs and member of daewg, Kiyoshi Horie, chairman and general manager of Asahi Pharmaceutical Technology Co., Ltd., Keita Ishibashi, deputy director of public relations project of Takeda pharmaceutical The two sides held in-depth exchanges on how to jointly promote pharmaceutical innovation and investment in Asia and meet clinical needs to be solved in the future At the meeting, chairman Zhang Dan first extended a warm welcome to JPMA's representative's visit, and mentioned that Japan, as the International Coordination Conference on technical requirements for registration of human drugs (hereinafter referred to as "ICH"), had China also hopes to join the ICH as soon as possible, which will speed up the research and development of innovative drugs and help new drugs to be applied in clinical practice faster and benefit patients Shingo Yamasaki and Atsushi hasuoka introduced the basic situation of JPMA and APAC respectively, and mentioned that the population of Asia accounts for 60% of the total population of the world, and the pharmaceutical market is growing rapidly at the rate of 16% every year, which has a very broad prospect Later, noriyuki Matsumoto introduced daewg's work in "information sharing, work network building, capacity building, special diseases in Asia, natural products", and expressed his willingness to work with China Pharmaceutical Council to jointly promote pharmaceutical innovation in Asia Chairman Zhang Dan focused on the main work of the China Council for the promotion of drugs in the near future In November 2016, CFDA held the "first China Pharmaceutical Innovation and investment conference" in Suzhou, attracting 320 pharmaceutical enterprises, more than 220 investment institutions and nearly 1500 participants It is the largest pharmaceutical innovation investment conference in Asia in recent years This year, the second China Pharmaceutical Innovation and investment conference will be held at the end of October, and JPMA representatives from Japan will be invited to attend In terms of internationalization, in May this year, the China Association for the promotion of drugs published a series of articles on the theme of "from imitation to innovation" in the internationally renowned journal Nature, demonstrating the remarkable achievements made in the transformation of Chinese medicine from imitation to innovation in the past decade President Wang Yinxiang believes that the open and information sharing platform established by daewg around the whole process from active ingredients to drug research and development plays a very important role in promoting innovative drug research and development China Council for the promotion of drugs should strengthen communication and exchange with JPMA and APAC, and work together to develop clinical treatment drugs for Asian patients with high incidence of diseases by using dsanj drug database Japan expressed strong interest in participating in the "Second China Pharmaceutical Innovation and investment conference", and said that Japan also holds the bio Japan conference every year, which will be held in October this year The two associations can carry out more in-depth cooperation and exchanges in promoting pharmaceutical innovation and investment in Asia Cheng Yinqi, Deputy Secretary General of China pharmaceutical promotion association, Lu Xiaoti, deputy director of international department and Ruan Xinxin, project manager attended the meeting.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.